Please ensure Javascript is enabled for purposes of website accessibility

Why Agile Therapeutics Stock Is Jumping Today

By George Budwell - May 4, 2020 at 12:07PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Agile's shares are heating up ahead of the company's Q1 earnings report.

What happened

Agile Therapeutics (AGRX -11.93%), a small-cap women's healthcare company, is starting the week off on the right foot. Specifically, the drugmaker's shares are up by 11.2% on extremely heavy volume, as of 10:40 a.m. EDT Monday.  

Unfortunately, the spark behind this double-digit move higher -- and enormous spike in volume -- isn't altogether clear at this point. Agile hasn't released any major news or noteworthy SEC filings in the past few weeks.

A young professional man pumping his fists in excitement while sitting at a desk with a laptop on it.

Image source: Getty Images.

So what

That said, the company is slated to release its first-quarter earnings report after the closing bell tomorrow. Although Wall Street isn't expecting much in the way of Q1 revenue from the company's newly approved once-a-week contraceptive patch known as Twirla, there could be some news on the partnering front. For their part, investors appear to be betting on Agile announcing something along these lines tomorrow. Twirla, after all, is undoubtedly more valuable in the hands of a big pharma with a full-blown women's healthcare unit. 

Now what

Is Agile's stock still a buy after this latest move northward? It all depends on how long you're willing to hold this early commercial-stage biotech stock. There's no evidence that a partnering deal is imminent and it might take Agile several years to establish Twirla as a major revenue generator. On the bright side, Twirla does have the potential to morph into a solid cash cow for the company in the years ahead. So if you're willing to buy and hold for at least five years, this small-cap biotech stock might be worth the risk.  

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Agile Therapeutics, Inc. Stock Quote
Agile Therapeutics, Inc.
AGRX
$0.56 (-11.93%) $0.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.